What is AICIS (and why it replaced NICNAS)?
The Australian Industrial Chemicals Introduction Scheme (AICIS) commenced on 1 July 2020, replacing the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) for the introduction of industrial chemicals in Australia. Under AICIS, introducers—importers and Australian manufacturers—must categorise each chemical introduction against the authorised pathways, maintain records, and in many cases submit declarations or dossiers to the regulatory authority before or as they supply the Australian market.
For trade partners, the headline is simple but easy to misread: many cosmetics are regulated as industrial chemicals under AICIS, not as “cosmetics law” in isolation. That means your moisturiser, cleanser, or colour cosmetic may require an AICIS introduction authorisation pathway even when it looks like a retail beauty SKU. The scheme is chemistry- and introduction-driven; marketing category labels on Tmall or Amazon do not decide the Australian regulator.
AICIS also interacts with inventory, reporting, and post-market expectations. First-time entrants should map every intentionally added ingredient—including fragrances and preservatives— against the industrial chemicals framework, then overlay therapeutic claims and product form rules that can shift some lines to the TGA. Treating AICIS as a paperwork afterthought is a common source of customs holds, retailer rejections, and insurance disputes.
If you are landing a broader consumer brand in Australia, pair chemical introductions with your operational plan for Australia market entry & 3PL so that compliance milestones align with purchase orders and channel listings.
What is the TGA (Therapeutic Goods Administration)?
The Therapeutic Goods Administration (TGA) regulates therapeutic goods supplied in Australia—medicines, medical devices, biologicals, and certain other products captured by the therapeutic goods framework. A product can be a therapeutic good because of what it is (e.g., a listed medicine), how it is presented (claims and context), or primary intended use inferred from labelling and promotion.
Sunscreens above specified SPF thresholds, products with acne treatment positioning in therapeutic terms, antiseptic hand rubs framed for clinical outcomes, and many “cosmeceutical” stories can trigger TGA obligations even when the factory still thinks of the SKU as skincare. The TGA pathway typically involves Australian Register of Therapeutic Goods (ARTG) inclusion or listing (depending on category and rules), GMP expectations where applicable, advertising restrictions, and ongoing pharmacovigilance-style obligations for some classes.
Importers sometimes assume that CE marking, US FDA cosmetic Voluntary Cosmetic Registration Program (VCRP) history, or Chinese filing records substitute for Australian requirements. They do not. Australian law stands alone; your task is to prove conformity to the correct Australian framework for each SKU and each claim set—not to the comfort narrative of another jurisdiction.
XYX helps teams translate factory documentation into an Australian regulatory story before marketing teams publish hero claims on packaging or livestreams.
Decision tree: AICIS vs TGA vs both
Use this sequence at concept stage—before you commit to carton copy and influencer scripts:
- General cosmetics without therapeutic positioning (cleanse, moisturise, fragrance, colour where permitted) typically fall under AICIS as industrial chemical introductions, with obligations tied to ingredient identity, introduction volume bands, and authorised introduction categories.
- Therapeutic claims and certain product types—for example anti-acne therapeutic claims, primary sunscreen products at regulated SPF levels, medicated shampoos positioned for therapeutic outcomes, or antibacterial claims framed as therapeutic—often require TGA pathways and ARTG involvement in addition to any chemical introduction considerations.
- Combination realities: a sunscreen marketed with cosmetic elegance may still be a therapeutic good; a “serum” with drug-like claims may need TGA assessment while its chemical components still require correct AICIS introduction handling. Dual-track programmes are normal for ambitious formulations.
When in doubt, run a structured claims audit: extract every sentence on the primary display panel, secondary panels, insert, retailer listing, and flagship short video. If any statement implies treatment, prevention, diagnosis, or measurable clinical outcome beyond cosmetic cleansing or appearance, escalate to TGA logic early. Retrofitting claims after import is more expensive than designing two compliant label variants at source.
For upstream factory engagement and specification control, see also China sourcing & OEM—compliance should be a purchase order clause, not a customs surprise.
AICIS introduction categories: reported, assessed, and evaluated
AICIS authorises introductions through several pathways; three labels appear constantly in importer conversations:
Reported introductions cover lower-risk introductions that meet defined criteria. They still carry record-keeping, annual declaration, and compliance duties; they are not “unregulated.” Volume thresholds and chemical identity rules matter; a change in supplier or purity profile can change the category.
Assessed introductions involve higher-risk profiles where pre-introduction assessment is required. Expect dossier-style work: hazard and exposure reasoning, stability of the supply chain, and disciplined technical writing. Timelines stretch when data gaps require new testing.
Evaluated introductions concern chemicals evaluated under NICNAS with certificates that continue under transitional arrangements—still not automatic; introducers must verify current applicability, certificate coverage, and any variation control when formulations evolve.
Category selection is legal-technical work. If your team only knows INCI marketing names, invest early in CAS-level bill of materials discipline and non-disclosure governance with the factory—without chemistry transparency, you cannot defend an introduction category under audit.
TGA and ARTG listing: what importers should expect
When a product is a therapeutic good, supply in Australia generally requires it to be entered in the ARTG unless a specific exemption applies (exemptions are narrow and fact-specific). The listing or registration pathway depends on classification, ingredients, indications, and applicable rules. Sponsors—often the Australian responsible entity—must maintain evidence, handle variations, and manage recalls and adverse event reporting where required.
Advertising therapeutic goods is heavily regulated; social proof and influencer language can inadvertently create therapeutic representations. Your Australian sponsor and marketing team should share a single approved claims matrix referenced by packaging, e-commerce, and paid media.
Parallel import and grey-market narratives rarely survive contact with Australian retail compliance desks. National pharmacy and grocery banners run vendor audits; inconsistent ARTG status or ambiguous responsible supplier identity blocks ranging.
Treat ARTG work as a programme with gates: formulation lock, evidence package, submission, labelling compliance, and post-approval change control—each gate should have an owner and a date.
Common mistakes importers make
Claim drift between markets. A claim acceptable on a domestic Chinese livestream may be therapeutic in Australia. Maintain jurisdiction-specific claim libraries, not one global master label.
Ingredient opacity. “Botanical blend” without compositional transparency prevents correct AICIS categorisation and blocks credible sponsor review for TGA lines.
Sunscreen confusion. Primary sunscreens sit in a heavily regulated lane; cosmetic products with incidental UV language are still sensitive. SPF marketing thresholds trigger expert review.
Single-regulator assumption. Teams pick AICIS or TGA emotionally—whichever sounds cheaper—instead of sequencing both when required.
Late insurance and retailer due diligence. Buyers now ask for introduction evidence and ARTG extracts before ranging; missing files delay revenue even when customs cleared the container.
Cost comparison and realistic timelines
Reported introduction programmes, when genuinely low complexity and well documented, can be faster and less expensive than full therapeutic registrations—but only if the facts support the category. Assessed introductions and TGA registrations scale with toxicology data quality, stability of sourcing, and whether you already maintain GMP-aligned manufacturing evidence.
Dual-track products (AICIS plus TGA) should be budgeted as separate workstreams with a shared technical data backbone. Typical first-time programmes benefit from a staged plan: freeze formulation, complete claims audit, lock supplier CoA packages, then run parallel regulatory drafting rather than sequential guesswork that extends warehouse rent.
Numbers change with product class and evidence gaps; use external counsel for legal opinions where borderline claims sit. XYX focuses on operational sequencing, document readiness, and partner coordination so specialists spend time on judgment, not chasing PDFs.
Document pack and governance checklist
Before you scale production, assemble a living compliance binder—not a static PDF archive. At minimum, importers should maintain version-controlled bills of materials with CAS identifiers, supplier certificates of analysis, stability summaries where relevant, manufacturing flow diagrams, and artwork proofs with claim call-outs highlighted against the approved matrix. For TGA lines, add evidence tables that map each indication to supporting data, and keep pharmacovigilance contact trees current even when sales volumes are still small.
Governance beats heroics: assign a single “regulatory owner” on the Chinese side and a single sponsor-aligned owner in Australia; run monthly change-control reviews that include procurement (substitutions happen quietly), QA (release parameters drift), and marketing (new TikTok scripts appear overnight). Introducers who treat compliance as a quarterly board topic rather than a shipping gate catch problems while they are still cheap to fix.
Retailers increasingly request evidence packs in structured formats—some provide vendor templates. Pre-building those templates internally accelerates ranging conversations and reduces the risk that a junior merchandiser mis-files your dossier against a competitor with cleaner metadata.
Finally, align SDS language with both transport and consumer labelling narratives; inconsistent hazard communication is a preventable source of customs queries and downstream workplace safety disputes.
How XYX helps with your compliance pathway
XYX Holdings supports Australia–China trade operators with bilingual programme management: aligning factory technical disclosures with Australian introduction strategy, coordinating specialist consultants where required, and connecting regulatory milestones with market entry logistics and 3PL so that your first shipment matches the story your sponsor will defend.
If you are evaluating a cosmetics or household chemistry line for Australia, bring your INCI list, draft artwork, and intended claims to contact—we will help you map AICIS and TGA touchpoints before you scale production.
Clear regulator choice is a competitive advantage: it shortens ranging conversations, reduces recall risk, and lets marketing invest confidently in compliant growth.